Business
SCYNEXIS Announces Preclinical Data on Ibrexafungerp and Azoles against Aspergillus Presented at the 9th Advances Against Aspergillosis and Mucormycosis Conference
Preclinical in vitro data showed synergistic activity against Aspergillus isolates from lung transplant recipientsSCYNEXIS is conducting two clinical trials
About this update from Scynexis, Inc.
[{"type":"text","content":"Preclinical in vitro data showed synergistic activity against Aspergillus isolates from lung transplant recipientsSCYNEXIS is conducting two clinical trials for patients suffering from Aspergillus infections: FURI evaluating ibrexafungerp as salvage therapy (alone or in combination) and SCYNERGIA evaluating ibrexafungerp as first-line therapy in combination with an azole JERSEY CITY, N.J., March 05, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that data from a preclinical study of oral ibrexafungerp in combination with azoles against Aspergillus species isolated from lung transplant recipients were presented at the 9th Advances Against Aspergillosis and Mucormycosis conference on February 27-29, 2020. These in vitro data showed synergistic activity of ibrexafungerp in combination with azoles against Aspergillus isolates. Ibrexafungerp is a broad-spectrum, IV/oral antifungal agent representing a novel therapeutic class, in late stage development for multiple indications, ranging from vaginal yeast infections to life-threatening fungal infections, including invasive aspergillosis.\n “Aspergillus is a common mold that can be deadly for patients with weak immune systems due to chemotherapy or transplants. Despite prophylaxis and treatment with the current standard of care, including azole therapies, the mortality rate among lung transplant patients remains high and will only grow as drug-resistant strains continue to emerge. It is imperative that we develop new weapons to use in the fight against invasive fungal infections, including aspergillosis,” said David Angulo, M.D., Chief Medical Officer of SCYNEXIS. “The data presented here strengthens our conviction that ibrexafungerp, as part of a combination regimen with azole agents, could play a role in combating Aspergillus infections. We are conducting multiple clinical trials evaluating ibrexafungerp for the treatment of invasive aspergillosis and other life-threatening fungal pathogens.” The preclinical study evaluated the in vitro activity of ibrexafungerp, alone or in combination with current azole treatments, against 51 Aspergillus isolates recovered from lung transplant recipients. It demonstrated synergistic activity again...